Literature DB >> 34529829

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Catalytic receptors.

Stephen Ph Alexander1, Doriano Fabbro2, Eamonn Kelly3, Alistair Mathie4, John A Peters5, Emma L Veale4, Jane F Armstrong5, Elena Faccenda6, Simon D Harding6, Adam J Pawson6, Christopher Southan6, Jamie A Davies6, Annie Beuve7, Peter Brouckaert8, Clare Bryant9, John C Burnett10, Richard W Farndale9, Andreas Friebe11, John Garthwaite12, Adrian J Hobbs13, Gavin E Jarvis14, Michaela Kuhn11, David MacEwan15, Tom P Monie9, Andreas Papapetropoulos16, Lincoln R Potter17, Harald H H W Schmidt18, Csaba Szabo19, Scott A Waldman20.   

Abstract

The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes over 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/bph.15541. Catalytic receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled receptors, ion channels, nuclear hormone receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2021, and supersedes data presented in the 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.
© 2021 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34529829     DOI: 10.1111/bph.15541

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   9.473


  15 in total

1.  A novel peptide inhibitor of Dll4-Notch1 signalling and its pro-angiogenic functions.

Authors:  Guofu Zhu; Ying Lin; Tandi Ge; Shekhar Singh; Hao Liu; Linlin Fan; Shumin Wang; Jordan Rhen; Dongyang Jiang; Yuyan Lyu; Yiheng Yin; Xiankai Li; Danielle S W Benoit; Weiming Li; Yawei Xu; Jinjiang Pang
Journal:  Br J Pharmacol       Date:  2022-01-11       Impact factor: 9.473

Review 2.  Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID-19; a systematic review and meta-analysis of randomized clinical trials.

Authors:  Driton Vela; Zana Vela-Gaxha; Mjellma Rexhepi; Rozafa Olloni; Violeta Hyseni; Rajmonda Nallbani
Journal:  Br J Clin Pharmacol       Date:  2021-11-30       Impact factor: 3.716

3.  Zinc protoporphyrin binding to telomerase complexes and inhibition of telomerase activity.

Authors:  Zhaowen Zhu; Huy Tran; Meleah M Mathahs; Brian D Fink; John A Albert; Thomas O Moninger; Jeffery L Meier; Ming Li; Warren N Schmidt
Journal:  Pharmacol Res Perspect       Date:  2021-12

4.  2-Deoxy-d-glucose induces deglycosylation of proinflammatory cytokine receptors and strongly reduces immunological responses in mouse models of inflammation.

Authors:  Ikuno Uehara; Mitsuko Kajita; Atsuko Tanimura; Shigeaki Hida; Munehiko Onda; Zenya Naito; Shinsuke Taki; Nobuyuki Tanaka
Journal:  Pharmacol Res Perspect       Date:  2022-04

Review 5.  New insights into the role of melatonin in diabetic cardiomyopathy.

Authors:  Keming Huang; Xianling Luo; Yi Zhong; Li Deng; Jian Feng
Journal:  Pharmacol Res Perspect       Date:  2022-02

6.  The effects of prolactin receptor blockade in a murine endometriosis interna model.

Authors:  Christiane Otto; Hannes-Friedrich Ulbrich; Christoph Freiberg
Journal:  Pharmacol Res Perspect       Date:  2022-02

Review 7.  Niclosamide-A promising treatment for COVID-19.

Authors:  Shivani Singh; Anne Weiss; James Goodman; Marie Fisk; Spoorthy Kulkarni; Ing Lu; Joanna Gray; Rona Smith; Morten Sommer; Joseph Cheriyan
Journal:  Br J Pharmacol       Date:  2022-04-11       Impact factor: 9.473

8.  Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: A pharmacometric model-based approach.

Authors:  Philippe Jacqmin; Christian Laveille; Eric Snoeck; Michael B Jordan; Franco Locatelli; Maria Ballabio; Cristina de Min
Journal:  Br J Clin Pharmacol       Date:  2021-12-21       Impact factor: 3.716

9.  Bruton's TK regulates myeloid cell recruitment during acute inflammation.

Authors:  Gareth S D Purvis; Haidee Aranda-Tavio; Keith M Channon; David R Greaves
Journal:  Br J Pharmacol       Date:  2022-03-15       Impact factor: 9.473

10.  Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies.

Authors:  Xiaohua Gong; Tao Ji; Xiang Liu; Xuejun Chen; Swamy Yeleswaram
Journal:  Pharmacol Res Perspect       Date:  2022-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.